Filing Details

Accession Number:
0001171843-17-005068
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-08-14 18:06:16
Reporting Period:
2017-08-14
Filing Date:
2017-08-14
Accepted Time:
2017-08-14 18:06:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582313 Xenon Pharmaceuticals Inc. XENE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1352908 R Michael Hayden C/O Xenon Pharmaceuticals Inc
200 - 3650 Gilmore Way
Burnaby A1 V5G 4W8
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2017-08-14 15,000 $2.75 161,187 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 75,886 Indirect By Wife
Common Shares 30,348 Indirect By Genworks Inc.
Footnotes
  1. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.745 to $2.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  2. Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.